vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $30.1M, roughly 1.3× Dominari Holdings Inc.). ImmunityBio, Inc. runs the higher net margin — -161.8% vs -438.1%, a 276.3% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 220.4%).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
DOMH vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $38.3M |
| Net Profit | $-131.8M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | -8.9% | -169.0% |
| Net Margin | -438.1% | -161.8% |
| Revenue YoY | 220.4% | 407.0% |
| Net Profit YoY | -12426.2% | -4.7% |
| EPS (diluted) | $-6.94 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $38.3M | ||
| Q3 25 | $50.8M | $32.1M | ||
| Q2 25 | $34.1M | $26.4M | ||
| Q1 25 | $8.1M | $16.5M | ||
| Q4 24 | $9.4M | $7.6M | ||
| Q3 24 | $4.0M | $6.1M | ||
| Q2 24 | $6.2M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $-131.8M | $-61.9M | ||
| Q3 25 | $125.2M | $-67.3M | ||
| Q2 25 | $16.6M | $-92.6M | ||
| Q1 25 | $-32.5M | $-129.6M | ||
| Q4 24 | $1.1M | $-59.2M | ||
| Q3 24 | $-4.2M | $-85.7M | ||
| Q2 24 | $-6.1M | — | ||
| Q1 24 | $-5.4M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -8.9% | -169.0% | ||
| Q3 25 | -3.1% | -173.5% | ||
| Q2 25 | -57.0% | -269.8% | ||
| Q1 25 | -394.6% | -390.1% | ||
| Q4 24 | 0.4% | -919.0% | ||
| Q3 24 | -79.1% | -1314.3% | ||
| Q2 24 | -44.3% | — | ||
| Q1 24 | -205.2% | — |
| Q4 25 | -438.1% | -161.8% | ||
| Q3 25 | 246.4% | -209.8% | ||
| Q2 25 | 48.7% | -350.3% | ||
| Q1 25 | -400.5% | -784.9% | ||
| Q4 24 | 11.4% | -783.4% | ||
| Q3 24 | -104.2% | -1404.0% | ||
| Q2 24 | -99.1% | — | ||
| Q1 24 | -398.0% | — |
| Q4 25 | $-6.94 | $-0.06 | ||
| Q3 25 | $7.27 | $-0.07 | ||
| Q2 25 | $1.12 | $-0.10 | ||
| Q1 25 | $-3.02 | $-0.15 | ||
| Q4 24 | $0.21 | $-0.08 | ||
| Q3 24 | $-0.67 | $-0.14 | ||
| Q2 24 | $-1.01 | — | ||
| Q1 24 | $-0.91 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $-500.5M |
| Total Assets | $112.9M | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $242.8M | ||
| Q3 25 | $176.2M | $257.8M | ||
| Q2 25 | $28.2M | $153.7M | ||
| Q1 25 | $18.9M | $61.6M | ||
| Q4 24 | $8.2M | $149.8M | ||
| Q3 24 | $7.2M | $130.4M | ||
| Q2 24 | $12.1M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | $69.4M | $-500.5M | ||
| Q3 25 | $210.2M | $-524.3M | ||
| Q2 25 | $88.6M | $-570.7M | ||
| Q1 25 | $42.4M | $-591.4M | ||
| Q4 24 | $39.9M | $-489.1M | ||
| Q3 24 | $38.3M | $-745.1M | ||
| Q2 24 | $42.4M | — | ||
| Q1 24 | $47.7M | — |
| Q4 25 | $112.9M | $501.9M | ||
| Q3 25 | $223.4M | $519.0M | ||
| Q2 25 | $109.3M | $402.1M | ||
| Q1 25 | $52.3M | $303.8M | ||
| Q4 24 | $47.1M | $382.9M | ||
| Q3 24 | $43.4M | $364.6M | ||
| Q2 24 | $49.1M | — | ||
| Q1 24 | $52.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-70.4M |
| Free Cash FlowOCF − Capex | — | $-71.3M |
| FCF MarginFCF / Revenue | — | -186.2% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-70.4M | ||
| Q3 25 | $-4.9M | $-68.9M | ||
| Q2 25 | $-353.0K | $-79.7M | ||
| Q1 25 | $1.2M | $-85.9M | ||
| Q4 24 | $-16.7M | $-85.1M | ||
| Q3 24 | $-4.7M | $-98.8M | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $-8.6M | — |
| Q4 25 | — | $-71.3M | ||
| Q3 25 | — | $-69.6M | ||
| Q2 25 | — | $-80.8M | ||
| Q1 25 | — | $-87.0M | ||
| Q4 24 | — | $-87.3M | ||
| Q3 24 | — | $-101.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -186.2% | ||
| Q3 25 | — | -217.2% | ||
| Q2 25 | — | -305.9% | ||
| Q1 25 | — | -526.9% | ||
| Q4 24 | — | -1155.4% | ||
| Q3 24 | — | -1663.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
IBRX
Segment breakdown not available.
